Portal de investigación
Daptomycin Plus Fosfomycin Versus Daptomycin Alone for Methicillin-resistant Staphylococcus aureus Bacteremia and Endocarditis: A Randomized Clinical Trial
Fecha de publicación:
Autores de I3PT
Participantes ajenos a I3PT
- Pujol, M
- Miro, JM
- Shaw, E
- Aguado, JM
- San-Juan, R
- Puig-Asensio, M
- Pigrau, C
- Calbo, E
- Montejo, M
- Rodriguez-Alvarez, R
- Garcia-Pais, MJ
- Pintado, V
- Escudero-Sanchez, R
- Lopez-Contreras, J
- Morata, L
- Montero, M
- Andres, M
- Pasquau, J
- Arenas, MDM
- Padilla, B
- Murillas, J
- Jover-Saenz, A
- Lopez-Cortes, LE
- Garcia-Pardo, G
- Videla, S
- Hereu, P
- Tebe, C
- Pallares, N
- Sanllorente, M
- Dominguez, MA
- Camara, J
- Ferrer, A
- Padulles, A
- Cuervo, G
- Carratala, J
- MRSA Bacteremia BACSARM Trial Inve
Grupos de Investigación
Abstract
Background. We aimed to determine whether daptomycin plus fosfomycin provides higher treatment success than daptomycin alone for methicillin-resistant Staphylococcus aureus (MRSA) bacteremia and endocarditis. Methods. A randomized (1:1) phase 3 superiority, open-label, and parallel group clinical trial of adult inpatients with MRSA bacteremia was conducted at 18 Spanish hospitals. Patients were randomly assigned to receive either 10 mg/kg of daptomycin intravenously daily plus 2 g of fosfomycin intravenously every 6 hours, or 10 mg/kg of daptomycin intravenously daily. Primary endpoint was treatment success 6 weeks after the end of therapy. Results. Of 167 patients randomized, 155 completed the trial and were assessed for the primary endpoint. Treatment success at 6 weeks after the end of therapy was achieved in 40 of 74 patients who received daptomycin plus fosfomycin and in 34 of 81 patients who were given daptomycin alone (54.1% vs 42.0%; relative risk, 1.29 [95% confidence interval, .93-1.8]; P = .135). At 6 weeks, daptomycin plus fosfomycin was associated with lower microbiologic failure (0 vs 9 patients; P = .003) and lower complicated bacteremia (16.2% vs 32.1%; P = .022). Adverse events leading to treatment discontinuation occurred in 13 of 74 patients (17.6%) receiving daptomycin plus fosfomycin, and in 4 of 81 patients (4.9%) receiving daptomycin alone (P = .018). Conclusions. Daptomycin plus fosfomycin provided 12% higher rate of treatment success than daptomycin alone, but this difference did not reach statistical significance. This antibiotic combination prevented microbiological failure and complicated bacteremia, but it was more often associated with adverse events.
Datos de la publicación
- ISSN/ISSNe:
- 1058-4838, 1537-6591
- Tipo:
- Article
- Páginas:
- 1517-1525
- DOI:
- 10.1093/cid/ciaa1081
- PubMed:
- 32725216
CLINICAL INFECTIOUS DISEASES OXFORD UNIV PRESS INC
Citas Recibidas en Web of Science: 77
Documentos
- No hay documentos
Filiaciones
Keywords
- MRSA; bacteremia; daptomycin; fosfomycin; clinical trial
Campos de Estudio
Financiación
Cita
Pujol M,Miro JM,Shaw E,Aguado JM,San R,Puig M,Pigrau C,Calbo E,Montejo M,Rodriguez R et al. Daptomycin Plus Fosfomycin Versus Daptomycin Alone for Methicillin-resistant Staphylococcus aureus Bacteremia and Endocarditis: A Randomized Clinical Trial. Clin. Infect. Dis. 2021. 72. (9):p. 1517-1525. DOI: 10.1093/cid/ciaa1081.
Pujol M,Miro JM,Shaw E,Aguado JM,San R,Puig M,Pigrau C,Calbo E,Montejo M,Rodriguez R,Garcia MJ,Pintado V,Escudero R,Lopez J,Morata L,Montero M,Andres M,Pasquau J,Arenas MDM,Padilla B,Murillas J,Jover A,Lopez LE,Garcia G,Gasch O,Videla S,Hereu P,Tebe C,Pallares N,Sanllorente M,Dominguez MA,Camara J,Ferrer A,Padulles A,Cuervo G,Carratala J,MRSA Bacteremia BACSARM Trial I. Daptomycin Plus Fosfomycin Versus Daptomycin Alone for Methicillin-resistant Staphylococcus aureus Bacteremia and Endocarditis: A Randomized Clinical Trial. Clin. Infect. Dis. 2021. 72. (9):p. 1517-1525. IF:20,999. (1).